Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Combined Treatment of Scopolamine and Group Iii Mglur Antagonist, Cppg, Exerts Antidepressant Activity Without Affecting Anxiety-Related Behaviors Publisher Pubmed



Ebrahimighiri M1 ; Khakpai F2 ; Zarrindast MR3, 4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biology, Faculty of Sciences, University of Zanjan, Zanjan, Iran
  2. 2. Cognitive and Neuroscience Research Center (CNRC), Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  3. 3. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Neuroendocrinology, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Physiology and Behavior Published:2020


Abstract

Clinical trials have revealed that the muscarinic receptor antagonist scopolamine produces a fast and potent antidepressant response. However, the anticholinergic adverse effects and the risk of psychosis at higher doses limit the widespread clinical use of scopolamine. Combination therapy of scopolamine and other antidepressants in treating depression has been suggested. Our experimentswere designed to examine the effects of the combining ineffective doses of scopolamine and a group III metabotropic glutamate receptor (mGluR) antagonist, CPPG, on depression- and anxiety-related behaviors in male NMRI mice. The forced swim test (FST) and the elevated plus maze (EPM) were selected to evaluate depression- and anxiety-related behaviors, respectively. Intraperitoneal (i.p.) administration of scopolamine (0.01-0.5 mg/kg) exerted profound antidepressive and anxiogenic effects. Intracerebroventricular (i.c.v.) administration of CPPG (12.5-50 nmol/mouse) elicited significant antidepressive and anxiolytic effects. Moreover, the ineffective dose of CPPG (12.5 nmol/mouse) plus ineffective doses of scopolamine (0.01 or 0.05 mg/kg) showed antidepressant-like effect while these combinations had no effect anxiety-related behaviors. It should be noted that none of the compounds altered locomotor activity. Results identify the combined administration of scopolamine and CPPG as a possible hopeful target in the future treatment of the depressive disorder. © 2020 Elsevier Inc.
Related Docs
1. Additive Interaction Between Scopolamine and Nitric Oxide Agents on Immobility in the Forced Swim Test But Not Exploratory Activity in the Hole-Board, Psychopharmacology (2019)
2. Synergistic Anxiolytic-Like Effect of Cppg and Harmaline in Non-Stressed and Acute Restraint Stress (Ars) Mice, Neuroscience Letters (2025)
3. Isobolographic Analysis of the Antidepressant Interaction in Two-Drug Combinations of Citalopram, Bupropion, and Scopolamine in Mice, Naunyn-Schmiedeberg's Archives of Pharmacology (2022)
4. The Effect of 5-Ht4 Serotonin Receptors in the Ca3 Hippocampal Region on D-Ap5-Induced Anxiolytic-Like Effects: Isobolographic Analyses, Behavioural Brain Research (2021)
5. The Effect of Urb597, Exercise or Their Combination on the Performance of 6-Ohda Mouse Model of Parkinson Disease in the Elevated Plus Maze, Tail Suspension Test and Step-Down Task, Metabolic Brain Disease (2021)
6. Hab-O Shefa, a Persian Medicine Compound for Maintenance Treatment of Opioid Dependence: Randomized Placebo-Controlled Clinical Trial, Journal of Alternative and Complementary Medicine (2020)
7. Urb597 Abrogates Anxiogenic and Depressive Behaviors in the Methamphetamine-Withdrawal Mice: Role of the Cannabinoid Receptor Type 1, Cannabinoid Receptor Type 2, and Transient Receptor Potential Vanilloid 1 Channels, Journal of Psychopharmacology (2021)
Experts (# of related papers)
Azarakhsh Mokri (1)